# Prognostic and Clinicopathological Significance of MUC Family Members in Colorectal Cancer: A Systematic Review and Meta-Analysis

Authors: Chao Li; Didi Zuo; Tao Liu; Libin Yin; Chenyao Li; Lei Wang
Journal: Gastroenterology Research and Practice
 (2019)

---

## Abstract

Objective. To assess the association between MUC expression levels in colorectal cancer (CRC) tissues and prognosis and investigate the associations between MUC expression levels and CRC clinicopathological characteristics. Methods. The PubMed, Embase, Cochrane Library, and Web of Science databases were searched from inception through September 13, 2019, to identify studies investigating the association between MUC expression levels in CRC tissues and prognosis. Pooled hazard ratios (HRs) or odds ratio (ORs) with 95% confidence intervals (CIs) were used to evaluate associations between MUC expression levels and prognosis or clinicopathological characteristics, respectively. The heterogeneity between studies was assessed by the I2 values, whereas the likelihood of publication bias was assessed by Egger’s linear regression and Begg’s rank correlation test. Results. Among 33 included studies (n=6032 patients), there were no associations between combined MUC phenotype expression levels and overall survival (OS) or disease-free survival (DFS)/relapse-free survival (RFS) in patients with CRC. In subgroup analyses, the upregulated MUC1 expression (HR=1.50; 95% CI, 1.29–1.74; P<0.00001) was associated with poor OS. However, the upregulated MUC2 expression (HR=0.64; 95% CI, 0.52–0.79; P<0.00001) was associated with better OS. Furthermore, a high level of MUC1 expression (HR=1.99; 95% CI, 0.99–3.99; P=0.05) was associated with shorter DFS/RFS. However, patients with a low level of MUC2 tumors showed better DFS/RFS than patients with a high level of MUC2 tumors (HR=0.71; 95% CI, 0.49–1.04; P=0.08; P=0.0.009, I2=67%) and MUC5AC expression (HR=0.56; 95% CI, 0.38–0.82; P=0.003) was associated with longer DFS/RFS. In addition, a high level of MUC1 expression was associated with CRC in the rectum, deeper invasion, lymph node metastasis, distant metastasis, advanced tumor stage, and lymphatic invasion. A high level of MUC2 expression had a protective effect. High secretion of MUC5AC is associated with colon cancer compared with rectal cancer. Conclusion. The protein expression of MUC1 might be a poor biomarker in colorectal cancer and might play a role in tumor transformation and metastasis. However, the protein expression of MUC2 expression might have a protective effect. Furthermore, randomized controlled trials (RCTs) of large patients are needed to confirm the results.


---

## Body

## 1. Introduction

Colorectal cancer (CRC) is among the most frequently diagnosed cancers in the United States (US) [1]. In 2018, an estimated 140,250 Americans will be diagnosed with CRC and 50,630 individuals will die from the disease [2]. Although morbidity and mortality in CRC are reduced by high-quality healthcare and healthy lifestyles, the 5-year overall survival (OS) rates after initial diagnosis remain at 67% for patients with rectal cancer and 64% for patients with colon cancer [1]. Furthermore, CRC survivors have a high risk of cancer recurrence [3, 4] and secondary tumors, particularly in the digestive system [5].The classic tumor, node, and metastasis (TNM) staging system is regarded as the standard prognostic parameter and forms the basis for treatment decisions in CRC [6]. However, since the TNM system fails to reflect the intrinsic biological heterogeneity of CRC, especially in patients with atypical early or occult metastases, only 40% of CRCs are diagnosed at an early stage and approximately 50% of recently diagnosed cases will progress to metastatic cancer [7]. In addition, the prognostic value of TNM in patients with CRC is suboptimal [8]. Currently, there is an unmet need for biomarkers that accurately predict CRC progression, metastasis, and treatment outcomes [9].In recent years, increasing attention has been given to the role of mucins (MUC) in the pathogenesis of cancer. MUC are a family of high molecular weight glycosylated proteins [10], which have a highly polymorphic tandem repeat in the central region [11]. At present, approximately 20 MUC have been identified. These can be divided into two major subfamilies, secreting gel-type mucins and transmembrane mucins, according to their structure and function [12]. MUC are usually expressed on the apical surfaces of normal glandular epithelial cells and luminal epithelial cells and have key functions in immunity, cell adhesion, and intracellular signaling [13]. Studies on the subcellular distribution of MUC and biochemical characteristics of malignant transformation and progression implicate MUC in tumorigenesis and metastasis [14–18], suggesting that abnormal MUC expression may be a predictive biomarker of CRC.Evidence suggests that MUC expression is involved in the invasion and metastasis of various malignancies, including gallbladder cancer [19], breast cancer [20], ovarian cancer [21], gastric carcinoma [22, 23], pancreatic carcinoma [24–26], ampullary cancer [27, 28], lung cancer [16, 29], prostate cancer [30], renal cell carcinoma [31], and appendiceal carcinoma [32]. However, the prognostic value of MUC expression in CRC remains controversial [33–37]. To clarify the inconsistent findings from previously published studies investigating the role of MUC in CRC, this meta-analysis was conducted to assess the association between MUC expression levels and prognosis in CRC and investigate the associations between MUC expression levels and several CRC clinicopathological characteristics.


## 2. Materials and Methods

This systematic review and meta-analysis is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline [38]. Basing on previously published studies, our study does not include any research with humans or animals, so ethical recognition and patient consent are not required.


### 2.1. Search Strategy

Two review authors independently searched the PubMed, Embase, Cochrane Library, and Web of Science databases from inception through September 13, 2019. Keywords included (“mucins” OR “mucin” OR “MUC”) AND (“colorectal cancer” OR “colorectal neoplasm” OR “colorectal tumor” OR “colonic cancer” OR “colon cancer” OR “rectal cancer” OR “CRC”) AND (“prognostic “OR “prognosis” OR “outcome” OR “survival”). A manual search of the reference lists of relevant articles was performed. Searches were limited to articles published in English or Chinese language.


### 2.2. Inclusion and Exclusion Criteria

The inclusion criteria were (1) study design: cohort study; (2) population: patients with CRC; (3) parameter: MUC expression levels in CRC tissues; and (4) outcome: association between MUC expression levels in CRC tissues and prognosis.The exclusion criteria were as follows: (1) duplicate publications; (2) in vitro or animal studies; (3) reviews, conference reports, meta-analyses, books, case reports, or letters; or (4) studies that reported insufficient data. When articles reported data from the same study, the most recent article was included.


### 2.3. Data Extraction

Two review authors independently extracted data from the eligible studies, including the surname of the first author, year, country, sample size, patients’ mean age, MUC phenotype, antibody for MUC, cut-off value for MUC, frequency of high MUC expression, detection method, TNM stage, histologic type, mean tumor dimensions, median follow-up, and outcomes. Disagreements about data extraction were resolved by discussion with a third reviewer until consensus was reached.


### 2.4. Quality Assessment

Two review authors independently conducted an assessment of the methodological quality of included studies using the Newcastle Ottawa Scale (NOS) [39]. The NOS assessed the quality of the enrolled groups, the comparability and outcomes of the study populations, and study quality on a scale from 0 to 9 points, with ≥7 considered high-quality research.Publication bias was evaluated using Egger’s linear regression and Begg’s rank correlation test [40].


### 2.5. Statistical Analysis

Statistical analyses were performed using Review Manager, version 5.3 (Cochrane Collaboration, Copenhagen, Denmark) and STATA, version 12.0 (Stata Corporation, College Station, TX, USA). Survival analysis was performed according to Moher et al. [38]. Hazard ratios (HRs) were directly extracted from included studies, or digitized and extracted using Engauge Digitizer version 4.1 (http://markummitchell.github.io/engauge-digitizer/) software when prognostic information was plotted as a Kaplan-Meier curve [41]. Pooled HRs with corresponding 95% confidence intervals (CIs) were used to assess the association between MUC expression levels (low vs. high) in CRC tissues and OS or disease-free survival (DFS)/relapse-free survival (RFS). Odds ratios (ORs) with 95% CIs were used to assess the impact of MUC expression levels on clinicopathological characteristics.Studies with significant heterogeneity were identified with the chi-squared test (P≤0.10) and the inconsistency index (I2≥50%) [42]. When significant heterogeneity was found, a random effects model was adopted. Otherwise, a fixed effects model is used. Subgroup analyses stratified by MUC phenotype and metaregression analysis were performed to explore sources of heterogeneity. The likelihood of publication bias was assessed by Egger’s linear regression and Begg’s rank correlation test. Sensitivity analysis evaluated the robustness of the data by omitting one study at a time. P<0.05 was considered statistically significant.


## 2.1. Search Strategy

Two review authors independently searched the PubMed, Embase, Cochrane Library, and Web of Science databases from inception through September 13, 2019. Keywords included (“mucins” OR “mucin” OR “MUC”) AND (“colorectal cancer” OR “colorectal neoplasm” OR “colorectal tumor” OR “colonic cancer” OR “colon cancer” OR “rectal cancer” OR “CRC”) AND (“prognostic “OR “prognosis” OR “outcome” OR “survival”). A manual search of the reference lists of relevant articles was performed. Searches were limited to articles published in English or Chinese language.


## 2.2. Inclusion and Exclusion Criteria

The inclusion criteria were (1) study design: cohort study; (2) population: patients with CRC; (3) parameter: MUC expression levels in CRC tissues; and (4) outcome: association between MUC expression levels in CRC tissues and prognosis.The exclusion criteria were as follows: (1) duplicate publications; (2) in vitro or animal studies; (3) reviews, conference reports, meta-analyses, books, case reports, or letters; or (4) studies that reported insufficient data. When articles reported data from the same study, the most recent article was included.


## 2.3. Data Extraction

Two review authors independently extracted data from the eligible studies, including the surname of the first author, year, country, sample size, patients’ mean age, MUC phenotype, antibody for MUC, cut-off value for MUC, frequency of high MUC expression, detection method, TNM stage, histologic type, mean tumor dimensions, median follow-up, and outcomes. Disagreements about data extraction were resolved by discussion with a third reviewer until consensus was reached.


## 2.4. Quality Assessment

Two review authors independently conducted an assessment of the methodological quality of included studies using the Newcastle Ottawa Scale (NOS) [39]. The NOS assessed the quality of the enrolled groups, the comparability and outcomes of the study populations, and study quality on a scale from 0 to 9 points, with ≥7 considered high-quality research.Publication bias was evaluated using Egger’s linear regression and Begg’s rank correlation test [40].


## 2.5. Statistical Analysis

Statistical analyses were performed using Review Manager, version 5.3 (Cochrane Collaboration, Copenhagen, Denmark) and STATA, version 12.0 (Stata Corporation, College Station, TX, USA). Survival analysis was performed according to Moher et al. [38]. Hazard ratios (HRs) were directly extracted from included studies, or digitized and extracted using Engauge Digitizer version 4.1 (http://markummitchell.github.io/engauge-digitizer/) software when prognostic information was plotted as a Kaplan-Meier curve [41]. Pooled HRs with corresponding 95% confidence intervals (CIs) were used to assess the association between MUC expression levels (low vs. high) in CRC tissues and OS or disease-free survival (DFS)/relapse-free survival (RFS). Odds ratios (ORs) with 95% CIs were used to assess the impact of MUC expression levels on clinicopathological characteristics.Studies with significant heterogeneity were identified with the chi-squared test (P≤0.10) and the inconsistency index (I2≥50%) [42]. When significant heterogeneity was found, a random effects model was adopted. Otherwise, a fixed effects model is used. Subgroup analyses stratified by MUC phenotype and metaregression analysis were performed to explore sources of heterogeneity. The likelihood of publication bias was assessed by Egger’s linear regression and Begg’s rank correlation test. Sensitivity analysis evaluated the robustness of the data by omitting one study at a time. P<0.05 was considered statistically significant.


## 3. Results

### 3.1. Search Results

A total of 1273 articles were identified from the electronic search of the databases, and 3 additional studies were obtained from the manual search of the reference lists of relevant articles. After excluding 492 duplicates, titles and abstracts were screened, and 726 studies that did not meet the inclusion criteria were excluded. The full text of 58 studies was retrieved for further review, and 8 articles that did not report an endpoint, 8 articles with insufficient data, and 9 conference abstracts were excluded. Finally, 33 observational studies [33–37, 43–70] were found eligible for inclusion in our review (Figure 1).Figure 1
Flow diagram of included studies.


### 3.2. Characteristics of the Included Studies

The characteristics of the included studies are shown in Table1. The 33 eligible studies were published between 1987 and 2019. The studies included a total of 6032 cases. The mean age of patients ranged from 54.3 to 72.0 years, and the median follow-up ranged from 18.0 to 116.0 months. All included studies evaluated the correlation between MUC expression levels in CRC tissues and prognosis. 31 studies evaluated MUC expression using immunohistochemistry (IHC), and 2 studies used reverse transcriptase polymerase chain reaction (qRT-PCR). Nine MUC phenotypes, determined by the expression of MUC1, MUC2, MUC3, MUC4, MUC5AC, MUC12, MUC16, MUC20, and sialomucin, were associated with prognosis in CRC. Various anti-MUC monoclonal antibodies were utilized to identify the MUC phenotypes, and each study applied a different cut-off point (low/high level) to assess MUC expression.Table 1
Characteristics of the included studies.
First author
Year
Country
Patient number
Detection method
Mean age (years)
Media follow-up (mounts)
Outcome
Mucins phenotype
Antibody
Cut-off value (high level)
High MUC expression
Adams
2009
Switzerland
938
IHC
70.5
128.0
OS
MUC2
NR
PP>5%
NR
Al-Maghrabi
2019
Saudi Arabia
128
IHC
NR
NR
OS/DFS
MUC2
MRQ-18
PP≥25%
36.7%
Baldus
2000
Germany
264
IHC
64.8
NR
OS
MUC1
NCL-MUC1
PP>5%
58.0%
Baldus
2004
Germany
205
IHC
65.0
NR
OS
MUC1
HMFG-2
PP>35%
49.8%
Betge
2016
Germany
381
IHC
68.5
NR
OS/DFS
MUC1
Ma695
PP>0%
64.0%
MUC2
Ccp-58
PP>0%
77.0%
MUC5AC
45M1
PP>0%
48.9%
MUC6
MCN6.01
PP>0%
28.7%
Dawson
1987
UK
358
IHC
65.7
18.0
OS
Sialomucin
High iron diamine-alcian blue
Blue staining
29.6%
Diaz
2018
Spain
96
IHC
65.9
NR
DFS
MUC1
Clone E29
PP≥50%
46.0%
Duncan
2007
UK
403
IHC
72.0
116.0
OS
MUC1
Ma695
PP≥30%
31.5%
MUC3
1143/B7
PP≥30%
73.9%
Elzagheid
2013
Libya
141
IHC
NR
77.0
OS/DFS
MUC2
MRQ-18
PP>0%
50.0%
Hiraga
1998
Japan
100
IHC
62.7
80.0
OS
MUC1
KL-6
PP>30%
71.0%
Imai
2013
Japan
250
IHC
66.9
NR
OS/RFS
MUC2
Ccp-58
PP≥25%
49.4%
MUC5AC
CLH2
PP≥1%
46.8%
Ionescu
2014
Romania
39
qRT-PCR
66.0
NR
OS
MUC12
NR
NR
NR
Kang
2011
Korea
229
IHC
NR
108
OS
MUC2
NR
Score≥6
24.2%
Kasprzak
2018
Poland
34
IHC
NR
NR
OS
MUC1
Ma552
PP≥2.57%
100%
MUC2
Ccp-58
PP≥4.97%
100%
Khanh
2013
Japan
206
IHC
NR
NR
OS/RFS
MUC1
Ma695
PP≥25%
62.6%
MUC2
Ccp-58
PP≥50%
32.5%
MUC4
1G8
PP≥50%
33.0%
MUC5AC
CLH2
PP≥5%
33.5%
Kimura
2000
Japan
110
IHC
63.1
68.5
OS
MUC1
KL-6
PP≥30%
69.1%
Kocer
2002
Turkey
41
IHC
56.3
NR
DFS
MUC5AC
45M1
ISS>0.1
34.1%
Kocer
2006
USA
30
IHC
59.0
39.0
OS
MUC5AC
45M1
PP>10%
60.0%
Lennerz
2016
USA
33
IHC
58.0
51.2
OS
MUC2
Ccp58
PP≥10%
84.0%
MUC5AC
CLH2
PP≥10%
45.0%
MUC6
CLH5
PP≥10%
0.0%
Manne
2000
USA
166
IHC
65.3
NR
OS
MUC1
DF3
SI≥0.5
39.8%
MUC2
Ccp58
SI≥0.5
80.7%
Matsuda
2010
Japan
569
IHC
68.0
NR
OS
MUC2
Anti-MUC2
PP≥10%
65.0%
MUC5AC
Anti-MUC5
PP≥10%
15.1%
MUC6
Anti-MUC6
PP≥10%
1.9%
Matsuyama
2010
Japan
100
qRT-PCR
65.1
27.0
DFS
MUC12
Rabbit polyclonal antibody
NR
NR
Perez
2008
Brazil
35
IHC
62.2
NR
OS/DFS
MUC1
Ma695
PP>10%
20.0%
MUC2
Ccp-58
PP>10%
65.7%
MUC5AC
CLH2
PP>10%
22.9%
Shanmugam
2010
USA
132
IHC
65.0
NR
OS
MUC4
Clone 8G7
ISS>2
24.2%
Sun
2018
China
118
IHC
54.3
57.0
OS/DFS
MUC1
MXB Biotechnologies
PP≥10%
14.4%
Streppel
2012
USA
39
IHC
63.6
NR
OS
MUC16
Monoclonal antibody
PP>0%
64.1%
Wang
2016
China
81
IHC
63.5
NR
OS
MUC1
ZM-0391
ISS>1
53.1%
Wang
2017
China
139
IHC
NR
NR
OS
MUC2
NCL-MUC2
PP>20%
48.2%
MUC5AC
NCL-MUC5
PP>20%
28.1%
Xiao
2013
China
150
IHC
55.0
NR
OS/DFS
MUC20
Mouse antihuman polyclonal antibody
ISS>2
60.7%
You
2006
China
203
IHC
NR
111.9
OS
MUC1
Ma695
IRS≥2
40.7%
Yu
2007
China
150
IHC
57.5
NR
OS
MUC1
Ma695
ISS≥2
45.3%
MUC2
Ccp-58
ISS≥2
52.6%
MUC5AC
45M1
ISS≥2
44.0%
Zhang
2008
Japan
77
IHC
64.9
NR
OS
MUC1
KL-6
SI (positive)
55.8%
Zwenger
2014
Argentina
90
IHC
NR
NR
OS
MUC1
HMFG1
Score>0
94.0%
MUC2
H300
Score>0
52.4%
NR: not reported; RT-PCR: reverse transcriptase polymerase chain reaction; IHC: immunohistochemistry; SI: staining intensity; PP: positive cell percentage; immunostaining score (ISS): PP∗SI (while groups I and II (absent and low) were considered negative expression).


### 3.3. Methodological Quality

According to the NOS, all included studies were of high methodological quality (score≥7) (Table S1).


### 3.4. MUC Expression and Overall Survival in CRC

The association between MUC expression levels in CRC tissues and OS was investigated in 41 datasets from 30 articles; each dataset represented various MUC phenotypes. The meta-analysis demonstrated no association between combined MUC phenotype expression levels and OS (HR=1.15; 95% CI, 0.95–1.40; P=0.14). There was evidence of significant heterogeneity between studies (P<0.00001, I2=75%). The source of the heterogeneity was investigated in a subgroup analysis stratified by specific MUC phenotype. The subgroup analysis demonstrated that a high level vs. a low level of MUC1 expression (HR=1.50; 95% CI, 1.29–1.74; P<0.00001; P=0.72, I2=0%) or a low level vs. a high level of MUC2 expression (HR=1.56; 95% CI, 1.27–1.92; P<0.00001; P=0.11, I2=36%) was associated with poor OS in patients with CRC. However, associations between the levels of MUC5AC (HR=1.41; 95% CI, 0.84–2.35; P=0.19; P=0.0002, I2=75%), other MUC phenotypes (HR=1.43; 95% CI, 0.91–2.26; P=0.12; P<0.00001, I2=81%), and OS were not significant (Figure 2).Figure 2
MUC expression and OS.


### 3.5. MUC Expression and Disease-Free Survival/Recurrence-Free Survival in CRC

The association between MUC expression level in CRC tissues and DFS/RFS was investigated in 19 datasets from 11 articles. The meta-analysis demonstrated no association between combined MUC phenotype expression levels and DFS/RFS (HR=0.98; 95% CI, 0.75–1.29; P=0.90). There was evidence of significant heterogeneity between studies (P<0.00001, I2=70%). The source of the heterogeneity was investigated in a subgroup analysis stratified by specific MUC phenotype. The subgroup analysis demonstrated that a high level vs. a low level of MUC1 expression (HR=1.99; 95% CI, 0.99–3.99; P=0.05; P=0.0001, I2=78%) or other MUC expression (HR=2.09; 95% CI, 1.27–3.42; P=0.003; P=0.51, I2=0%) was associated with shorter DFS/RFS in patients with CRC. However, a high level vs. a low level of MUC5AC expression (HR=0.56; 95% CI, 0.38–0.82; P=0.003; P=0.69, I2=0%) was associated with longer DFS/RFS and patients with a low level of MUC2 tumors showed better DFS/RFS than patients with a high level of MUC2 tumors (HR=0.71; 95% CI, 0.49–1.04; P=0.08; P=0.0.009, I2=67%).(Figure 3).Figure 3
MUC expression and DFSRFS.


### 3.6. MUC Expression and CRC Clinicopathological Characteristics

The meta-analysis demonstrated no association between combined MUC phenotype expression levels and CRC clinicopathological characteristics. In all analyses, there was evidence of significant heterogeneity between studies. The source of the heterogeneity was investigated in subgroup analyses stratified by specific MUC phenotype (Table2).Table 2
Meta-analysis of the correlation between MUC expression and clinicopathological factors of colorectal cancer.
Clinicopathological parameter
Mucins phenotype
No. of studies
OR (95% CI)
Analysis model
Test for overall effect
Heterogeneity
Z test
P value
I2 (%)
P value
TNM stage (III/IV vs. I/II)
MUC1
11
2.17 (1.31-3.59)
Random
3.03
0.002
83
<0.00001
MUC2
7
0.52 (0.36-0.76)
Random
3.35
0.0008
52
0.05
MUC5AC
8
1.00 (0.67-1.49)
Random
0.01
0.99
55
0.03
Depth of invasion (T3/T4 vs. T1/T2)
MUC1
11
1.79 (1.41-2.26)
Fixed
4.86
<0.00001
40
0.08
MUC2
6
0.65 (0.37-1.13)
Random
1.53
0.13
63
0.02
MUC5AC
4
0.64 (0.35-1.18)
Random
1.42
0.15
61
0.05
Lymph node metastasis (+ vs. -)
MUC1
10
2.45 (1.38-4.35)
Random
3.07
0.002
81
<0.00001
MUC2
8
0.59 (0.47-0.73)
Fixed
4.64
<0.00001
48
0.06
MUC5AC
7
1.07 (0.67-1.72)
Random
0.29
0.77
67
0.006
Tumor site (colon vs. rectum)
MUC1
7
0.79 (0.63-0.98)
Fixed
2.12
0.03
0
0.63
MUC2
5
1.64 (1.01-2.67)
Random
2.02
0.04
55
0.06
MUC5AC
6
1.97 (1.48-2.62)
Fixed
4.63
<0.00001
49
0.08
Distant metastasis (+ vs. -)
MUC1
3
2.47 (1.47-4.13)
Fixed
3.43
0.0006
49
0.14
MUC2
3
0.83 (0.48-1.41)
Fixed
0.70
0.49
0
0.61
MUC5AC
2
0.86 (0.15-4.87)
Random
0.17
0.87
73
0.06
Lymphatic invasion (+ vs. -)
MUC1
5
3.39 (1.69-9.14)
Random
3.19
0.001
72
0.007
MUC2
3
0.53 (0.27-1.03)
Random
1.88
0.06
60
0.08
MUC5AC
4
0.76 (0.55-1.05)
Fixed
1.64
0.10
20
0.29
Mucinous component (high vs. low)
MUC1
7
0.71 (0.42-1.19)
Random
1.31
0.19
59
0.02
MUC2
2
14.46 (1.71-121.97)
Random
2.46
0.01
59
0.12
MUC5AC
3
1.41 (0.85-2.34)
Fixed
1.32
0.19
0
0.62
Gender (male vs. female)
MUC1
7
1.10 (0.86-1.41)
Fixed
0.77
0.44
0
0.75
MUC2
7
0.87 (0.68-1.12)
Fixed
1.07
0.29
8
0.29
MUC5AC
6
0.93 (0.69-1.24)
Random
<0.00001
1.00
55
0.005
Tumor size (large vs. small)
MUC1
4
0.77 (0.53-1.12)
Fixed
1.38
0.17
19
0.30
MUC2
2
0.70 (0.47-1.05)
Fixed
1.73
0.08
0
0.39
MUC5AC
2
0.80 (0.48-1.32)
Fixed
0.87
0.38
0
0.41
Histological grade (3 vs. 1 and 2)
MUC1
12
1.39 (0.87-2.21)
Random
1.39
0.16
66
0.0007
MUC2
7
0.75 (0.56-0.99)
Fixed
2.02
0.04
44
0.10
MUC5AC
5
1.44 (0.70-2.97)
Random
0.99
0.32
79
0.0007
RR: risk ratio; Random: random effects model; Fixed: fixed.A high level of MUC1 expression (III/IV vs. I/II:OR=2.17, 95% CI=1.31–3.59, P=0.002) was associated with advanced tumor stage in patients with CRC than MUC2 expression (III/IV vs. I/II: OR=0.52, 95% CI=0.36–0.76, P=0.0008), but the association between MUC5AC expression and tumor stage was not significant.A high level of MUC1 expression (T3/T4 vs. T1/T2:OR=1.79, 95% CI=1.41–2.26, P<0.00001) was associated with deeper invasion in patients with CRC, but the association between MUC5AC and MUC2 expression and depth of invasion was not significant.A high level of MUC1 expression (positive vs. negative:OR=2.45, 95% CI=1.38–4.35, P=0.002) was associated with lymph node metastasis in patients with CRC than MUC2 expression (positive vs. negative: OR=0.59, 95% CI=0.47–0.73, P<0.00001), but the association between MUC5AC expression and lymph node metastasis was not significant.A high level of MUC1 expression (positive vs. negative:OR=0.79, 95% CI=0.63–0.98, P=0.03) was associated with rectum cancer. However, the elevated MUC2 expression (positive vs. negative: OR=1.64, 95% CI=1.01–2.67, P=0.04) and MUC5AC expression (positive vs. negative: OR=1.97, 95% CI=1.48–2.62, P<0.00001) were associated with colon cancer.A high level of MUC1 expression was associated with distant metastasis (positive vs. negative:OR=2.47, 95% CI=1.47–4.13, P=0.0006) and lymphatic invasion (positive vs. negative: OR=3.39, 95% CI=1.69–9.14, P=0.001) in patients with CRC. A high level of MUC2 expression was associated mucinous cancer (high vs. low: OR=14.46, 95% CI=1.71–121.97, P=0.01) and low histological grade (3 vs. 1 and 2: OR=0.75, 95% CI=0.56–0.99, P=0.04).There were no associations between the expression levels of any MUC phenotypes and other clinicopathological characteristics, including gender or tumor size.


### 3.7. Sensitivity Analysis and Publication Bias

Sensitivity analysis omitting one study at a time demonstrated the associations of MUC family members’ expression with OS (Figure4) and DFS/RFS (Figure 5) in CRC were robust. Begg’s rank correlation test and Egger’s linear regression showed no publication bias among studies investigating OS (Figure 6) and DFS/RFS (Figure 7).Figure 4
Sensitivity analysis for MUC expression ((a): MUC1, (b): MUC2, (c): MUC5AC, (d): Others MUC) and OS.
(a)
(b)
(c)
(d)Figure 5
Sensitivity analysis for MUC expression ((a): MUC1, (b): MUC2, (c): MUC5AC, (d): Others MUC) and DFS/RFS.
(a)
(b)
(c)
(d)Figure 6
Publication bias for MUC expression ((a): MUC1, (b): M UC2, (c): MUC5AC, (d): Others MUC) and OS.
(a)
(b)
(c)
(d)Figure 7
Publication bias for MUC expression ((a): MUC1, (b): MUC2, (c): MUC5AC, (d): Others MUC) and DFS/RFS.
(a)
(b)
(c)
(d)


### 3.8. Metaregression

Metaregression was performed to explore the factors influencing the association of MUC expression with OS and DFS/RFS in CRC. None of the covariates (cut-off value, antibody, TNM stage, country, and years) analyzed were identified as potential sources of heterogeneity (Table3).Table 3
Results of meta-regression analysis exploring the source of heterogeneity with OS and DFS/RFS.
Mucins phenotype
Covariates
Univariate analysis (OS)
Univariate analysis (DFS)
Coefficient
SE
P value
Coefficient
SE
P value
MUC1
Antibody
0.055
0.087
0.538
-0.142
0.882
0.883
Cut-off value
0.0297
0.032
0.369
0.155
0.295
0.635
TNM stage
0.365
0.324
0.281
0.773
1.106
0.535
Country
0.048
0.462
0.323
0.155
0.295
0.635
Year
-0.001
0.014
0.964
-0.077
0.115
0.552
MUC2
Antibody
-0.204
0.215
0.367
0.550
0.252
0.094
Cut-off value
-0.027
0.043
0.552
-0.030
0.221
0.898
TNM stage
-0.309
0.124
0.054
-0.270
0.838
0.763
Country
0.007
0.048
0.891
0.180
0.050
0.023
Year
0.036
0.030
0.264
0.108
0.030
0.022
MUC5AC
Antibody
0.464
0.269
0.135
-0.139
0.434
0.769
Cut-off value
0.187
0.158
0.282
-0.248
0.193
0.288
TNM stage
0.923
0.211
0.055
-0.652
0.961
0.546
Country
0.250
0.240
0.339
-0.379
0.293
0.287
Year
0.135
0.073
0.859
0.102
0.069
0.236


## 3.1. Search Results

A total of 1273 articles were identified from the electronic search of the databases, and 3 additional studies were obtained from the manual search of the reference lists of relevant articles. After excluding 492 duplicates, titles and abstracts were screened, and 726 studies that did not meet the inclusion criteria were excluded. The full text of 58 studies was retrieved for further review, and 8 articles that did not report an endpoint, 8 articles with insufficient data, and 9 conference abstracts were excluded. Finally, 33 observational studies [33–37, 43–70] were found eligible for inclusion in our review (Figure 1).Figure 1
Flow diagram of included studies.


## 3.2. Characteristics of the Included Studies

The characteristics of the included studies are shown in Table1. The 33 eligible studies were published between 1987 and 2019. The studies included a total of 6032 cases. The mean age of patients ranged from 54.3 to 72.0 years, and the median follow-up ranged from 18.0 to 116.0 months. All included studies evaluated the correlation between MUC expression levels in CRC tissues and prognosis. 31 studies evaluated MUC expression using immunohistochemistry (IHC), and 2 studies used reverse transcriptase polymerase chain reaction (qRT-PCR). Nine MUC phenotypes, determined by the expression of MUC1, MUC2, MUC3, MUC4, MUC5AC, MUC12, MUC16, MUC20, and sialomucin, were associated with prognosis in CRC. Various anti-MUC monoclonal antibodies were utilized to identify the MUC phenotypes, and each study applied a different cut-off point (low/high level) to assess MUC expression.Table 1
Characteristics of the included studies.
First author
Year
Country
Patient number
Detection method
Mean age (years)
Media follow-up (mounts)
Outcome
Mucins phenotype
Antibody
Cut-off value (high level)
High MUC expression
Adams
2009
Switzerland
938
IHC
70.5
128.0
OS
MUC2
NR
PP>5%
NR
Al-Maghrabi
2019
Saudi Arabia
128
IHC
NR
NR
OS/DFS
MUC2
MRQ-18
PP≥25%
36.7%
Baldus
2000
Germany
264
IHC
64.8
NR
OS
MUC1
NCL-MUC1
PP>5%
58.0%
Baldus
2004
Germany
205
IHC
65.0
NR
OS
MUC1
HMFG-2
PP>35%
49.8%
Betge
2016
Germany
381
IHC
68.5
NR
OS/DFS
MUC1
Ma695
PP>0%
64.0%
MUC2
Ccp-58
PP>0%
77.0%
MUC5AC
45M1
PP>0%
48.9%
MUC6
MCN6.01
PP>0%
28.7%
Dawson
1987
UK
358
IHC
65.7
18.0
OS
Sialomucin
High iron diamine-alcian blue
Blue staining
29.6%
Diaz
2018
Spain
96
IHC
65.9
NR
DFS
MUC1
Clone E29
PP≥50%
46.0%
Duncan
2007
UK
403
IHC
72.0
116.0
OS
MUC1
Ma695
PP≥30%
31.5%
MUC3
1143/B7
PP≥30%
73.9%
Elzagheid
2013
Libya
141
IHC
NR
77.0
OS/DFS
MUC2
MRQ-18
PP>0%
50.0%
Hiraga
1998
Japan
100
IHC
62.7
80.0
OS
MUC1
KL-6
PP>30%
71.0%
Imai
2013
Japan
250
IHC
66.9
NR
OS/RFS
MUC2
Ccp-58
PP≥25%
49.4%
MUC5AC
CLH2
PP≥1%
46.8%
Ionescu
2014
Romania
39
qRT-PCR
66.0
NR
OS
MUC12
NR
NR
NR
Kang
2011
Korea
229
IHC
NR
108
OS
MUC2
NR
Score≥6
24.2%
Kasprzak
2018
Poland
34
IHC
NR
NR
OS
MUC1
Ma552
PP≥2.57%
100%
MUC2
Ccp-58
PP≥4.97%
100%
Khanh
2013
Japan
206
IHC
NR
NR
OS/RFS
MUC1
Ma695
PP≥25%
62.6%
MUC2
Ccp-58
PP≥50%
32.5%
MUC4
1G8
PP≥50%
33.0%
MUC5AC
CLH2
PP≥5%
33.5%
Kimura
2000
Japan
110
IHC
63.1
68.5
OS
MUC1
KL-6
PP≥30%
69.1%
Kocer
2002
Turkey
41
IHC
56.3
NR
DFS
MUC5AC
45M1
ISS>0.1
34.1%
Kocer
2006
USA
30
IHC
59.0
39.0
OS
MUC5AC
45M1
PP>10%
60.0%
Lennerz
2016
USA
33
IHC
58.0
51.2
OS
MUC2
Ccp58
PP≥10%
84.0%
MUC5AC
CLH2
PP≥10%
45.0%
MUC6
CLH5
PP≥10%
0.0%
Manne
2000
USA
166
IHC
65.3
NR
OS
MUC1
DF3
SI≥0.5
39.8%
MUC2
Ccp58
SI≥0.5
80.7%
Matsuda
2010
Japan
569
IHC
68.0
NR
OS
MUC2
Anti-MUC2
PP≥10%
65.0%
MUC5AC
Anti-MUC5
PP≥10%
15.1%
MUC6
Anti-MUC6
PP≥10%
1.9%
Matsuyama
2010
Japan
100
qRT-PCR
65.1
27.0
DFS
MUC12
Rabbit polyclonal antibody
NR
NR
Perez
2008
Brazil
35
IHC
62.2
NR
OS/DFS
MUC1
Ma695
PP>10%
20.0%
MUC2
Ccp-58
PP>10%
65.7%
MUC5AC
CLH2
PP>10%
22.9%
Shanmugam
2010
USA
132
IHC
65.0
NR
OS
MUC4
Clone 8G7
ISS>2
24.2%
Sun
2018
China
118
IHC
54.3
57.0
OS/DFS
MUC1
MXB Biotechnologies
PP≥10%
14.4%
Streppel
2012
USA
39
IHC
63.6
NR
OS
MUC16
Monoclonal antibody
PP>0%
64.1%
Wang
2016
China
81
IHC
63.5
NR
OS
MUC1
ZM-0391
ISS>1
53.1%
Wang
2017
China
139
IHC
NR
NR
OS
MUC2
NCL-MUC2
PP>20%
48.2%
MUC5AC
NCL-MUC5
PP>20%
28.1%
Xiao
2013
China
150
IHC
55.0
NR
OS/DFS
MUC20
Mouse antihuman polyclonal antibody
ISS>2
60.7%
You
2006
China
203
IHC
NR
111.9
OS
MUC1
Ma695
IRS≥2
40.7%
Yu
2007
China
150
IHC
57.5
NR
OS
MUC1
Ma695
ISS≥2
45.3%
MUC2
Ccp-58
ISS≥2
52.6%
MUC5AC
45M1
ISS≥2
44.0%
Zhang
2008
Japan
77
IHC
64.9
NR
OS
MUC1
KL-6
SI (positive)
55.8%
Zwenger
2014
Argentina
90
IHC
NR
NR
OS
MUC1
HMFG1
Score>0
94.0%
MUC2
H300
Score>0
52.4%
NR: not reported; RT-PCR: reverse transcriptase polymerase chain reaction; IHC: immunohistochemistry; SI: staining intensity; PP: positive cell percentage; immunostaining score (ISS): PP∗SI (while groups I and II (absent and low) were considered negative expression).


## 3.3. Methodological Quality

According to the NOS, all included studies were of high methodological quality (score≥7) (Table S1).


## 3.4. MUC Expression and Overall Survival in CRC

The association between MUC expression levels in CRC tissues and OS was investigated in 41 datasets from 30 articles; each dataset represented various MUC phenotypes. The meta-analysis demonstrated no association between combined MUC phenotype expression levels and OS (HR=1.15; 95% CI, 0.95–1.40; P=0.14). There was evidence of significant heterogeneity between studies (P<0.00001, I2=75%). The source of the heterogeneity was investigated in a subgroup analysis stratified by specific MUC phenotype. The subgroup analysis demonstrated that a high level vs. a low level of MUC1 expression (HR=1.50; 95% CI, 1.29–1.74; P<0.00001; P=0.72, I2=0%) or a low level vs. a high level of MUC2 expression (HR=1.56; 95% CI, 1.27–1.92; P<0.00001; P=0.11, I2=36%) was associated with poor OS in patients with CRC. However, associations between the levels of MUC5AC (HR=1.41; 95% CI, 0.84–2.35; P=0.19; P=0.0002, I2=75%), other MUC phenotypes (HR=1.43; 95% CI, 0.91–2.26; P=0.12; P<0.00001, I2=81%), and OS were not significant (Figure 2).Figure 2
MUC expression and OS.


## 3.5. MUC Expression and Disease-Free Survival/Recurrence-Free Survival in CRC

The association between MUC expression level in CRC tissues and DFS/RFS was investigated in 19 datasets from 11 articles. The meta-analysis demonstrated no association between combined MUC phenotype expression levels and DFS/RFS (HR=0.98; 95% CI, 0.75–1.29; P=0.90). There was evidence of significant heterogeneity between studies (P<0.00001, I2=70%). The source of the heterogeneity was investigated in a subgroup analysis stratified by specific MUC phenotype. The subgroup analysis demonstrated that a high level vs. a low level of MUC1 expression (HR=1.99; 95% CI, 0.99–3.99; P=0.05; P=0.0001, I2=78%) or other MUC expression (HR=2.09; 95% CI, 1.27–3.42; P=0.003; P=0.51, I2=0%) was associated with shorter DFS/RFS in patients with CRC. However, a high level vs. a low level of MUC5AC expression (HR=0.56; 95% CI, 0.38–0.82; P=0.003; P=0.69, I2=0%) was associated with longer DFS/RFS and patients with a low level of MUC2 tumors showed better DFS/RFS than patients with a high level of MUC2 tumors (HR=0.71; 95% CI, 0.49–1.04; P=0.08; P=0.0.009, I2=67%).(Figure 3).Figure 3
MUC expression and DFSRFS.


## 3.6. MUC Expression and CRC Clinicopathological Characteristics

The meta-analysis demonstrated no association between combined MUC phenotype expression levels and CRC clinicopathological characteristics. In all analyses, there was evidence of significant heterogeneity between studies. The source of the heterogeneity was investigated in subgroup analyses stratified by specific MUC phenotype (Table2).Table 2
Meta-analysis of the correlation between MUC expression and clinicopathological factors of colorectal cancer.
Clinicopathological parameter
Mucins phenotype
No. of studies
OR (95% CI)
Analysis model
Test for overall effect
Heterogeneity
Z test
P value
I2 (%)
P value
TNM stage (III/IV vs. I/II)
MUC1
11
2.17 (1.31-3.59)
Random
3.03
0.002
83
<0.00001
MUC2
7
0.52 (0.36-0.76)
Random
3.35
0.0008
52
0.05
MUC5AC
8
1.00 (0.67-1.49)
Random
0.01
0.99
55
0.03
Depth of invasion (T3/T4 vs. T1/T2)
MUC1
11
1.79 (1.41-2.26)
Fixed
4.86
<0.00001
40
0.08
MUC2
6
0.65 (0.37-1.13)
Random
1.53
0.13
63
0.02
MUC5AC
4
0.64 (0.35-1.18)
Random
1.42
0.15
61
0.05
Lymph node metastasis (+ vs. -)
MUC1
10
2.45 (1.38-4.35)
Random
3.07
0.002
81
<0.00001
MUC2
8
0.59 (0.47-0.73)
Fixed
4.64
<0.00001
48
0.06
MUC5AC
7
1.07 (0.67-1.72)
Random
0.29
0.77
67
0.006
Tumor site (colon vs. rectum)
MUC1
7
0.79 (0.63-0.98)
Fixed
2.12
0.03
0
0.63
MUC2
5
1.64 (1.01-2.67)
Random
2.02
0.04
55
0.06
MUC5AC
6
1.97 (1.48-2.62)
Fixed
4.63
<0.00001
49
0.08
Distant metastasis (+ vs. -)
MUC1
3
2.47 (1.47-4.13)
Fixed
3.43
0.0006
49
0.14
MUC2
3
0.83 (0.48-1.41)
Fixed
0.70
0.49
0
0.61
MUC5AC
2
0.86 (0.15-4.87)
Random
0.17
0.87
73
0.06
Lymphatic invasion (+ vs. -)
MUC1
5
3.39 (1.69-9.14)
Random
3.19
0.001
72
0.007
MUC2
3
0.53 (0.27-1.03)
Random
1.88
0.06
60
0.08
MUC5AC
4
0.76 (0.55-1.05)
Fixed
1.64
0.10
20
0.29
Mucinous component (high vs. low)
MUC1
7
0.71 (0.42-1.19)
Random
1.31
0.19
59
0.02
MUC2
2
14.46 (1.71-121.97)
Random
2.46
0.01
59
0.12
MUC5AC
3
1.41 (0.85-2.34)
Fixed
1.32
0.19
0
0.62
Gender (male vs. female)
MUC1
7
1.10 (0.86-1.41)
Fixed
0.77
0.44
0
0.75
MUC2
7
0.87 (0.68-1.12)
Fixed
1.07
0.29
8
0.29
MUC5AC
6
0.93 (0.69-1.24)
Random
<0.00001
1.00
55
0.005
Tumor size (large vs. small)
MUC1
4
0.77 (0.53-1.12)
Fixed
1.38
0.17
19
0.30
MUC2
2
0.70 (0.47-1.05)
Fixed
1.73
0.08
0
0.39
MUC5AC
2
0.80 (0.48-1.32)
Fixed
0.87
0.38
0
0.41
Histological grade (3 vs. 1 and 2)
MUC1
12
1.39 (0.87-2.21)
Random
1.39
0.16
66
0.0007
MUC2
7
0.75 (0.56-0.99)
Fixed
2.02
0.04
44
0.10
MUC5AC
5
1.44 (0.70-2.97)
Random
0.99
0.32
79
0.0007
RR: risk ratio; Random: random effects model; Fixed: fixed.A high level of MUC1 expression (III/IV vs. I/II:OR=2.17, 95% CI=1.31–3.59, P=0.002) was associated with advanced tumor stage in patients with CRC than MUC2 expression (III/IV vs. I/II: OR=0.52, 95% CI=0.36–0.76, P=0.0008), but the association between MUC5AC expression and tumor stage was not significant.A high level of MUC1 expression (T3/T4 vs. T1/T2:OR=1.79, 95% CI=1.41–2.26, P<0.00001) was associated with deeper invasion in patients with CRC, but the association between MUC5AC and MUC2 expression and depth of invasion was not significant.A high level of MUC1 expression (positive vs. negative:OR=2.45, 95% CI=1.38–4.35, P=0.002) was associated with lymph node metastasis in patients with CRC than MUC2 expression (positive vs. negative: OR=0.59, 95% CI=0.47–0.73, P<0.00001), but the association between MUC5AC expression and lymph node metastasis was not significant.A high level of MUC1 expression (positive vs. negative:OR=0.79, 95% CI=0.63–0.98, P=0.03) was associated with rectum cancer. However, the elevated MUC2 expression (positive vs. negative: OR=1.64, 95% CI=1.01–2.67, P=0.04) and MUC5AC expression (positive vs. negative: OR=1.97, 95% CI=1.48–2.62, P<0.00001) were associated with colon cancer.A high level of MUC1 expression was associated with distant metastasis (positive vs. negative:OR=2.47, 95% CI=1.47–4.13, P=0.0006) and lymphatic invasion (positive vs. negative: OR=3.39, 95% CI=1.69–9.14, P=0.001) in patients with CRC. A high level of MUC2 expression was associated mucinous cancer (high vs. low: OR=14.46, 95% CI=1.71–121.97, P=0.01) and low histological grade (3 vs. 1 and 2: OR=0.75, 95% CI=0.56–0.99, P=0.04).There were no associations between the expression levels of any MUC phenotypes and other clinicopathological characteristics, including gender or tumor size.


## 3.7. Sensitivity Analysis and Publication Bias

Sensitivity analysis omitting one study at a time demonstrated the associations of MUC family members’ expression with OS (Figure4) and DFS/RFS (Figure 5) in CRC were robust. Begg’s rank correlation test and Egger’s linear regression showed no publication bias among studies investigating OS (Figure 6) and DFS/RFS (Figure 7).Figure 4
Sensitivity analysis for MUC expression ((a): MUC1, (b): MUC2, (c): MUC5AC, (d): Others MUC) and OS.
(a)
(b)
(c)
(d)Figure 5
Sensitivity analysis for MUC expression ((a): MUC1, (b): MUC2, (c): MUC5AC, (d): Others MUC) and DFS/RFS.
(a)
(b)
(c)
(d)Figure 6
Publication bias for MUC expression ((a): MUC1, (b): M UC2, (c): MUC5AC, (d): Others MUC) and OS.
(a)
(b)
(c)
(d)Figure 7
Publication bias for MUC expression ((a): MUC1, (b): MUC2, (c): MUC5AC, (d): Others MUC) and DFS/RFS.
(a)
(b)
(c)
(d)


## 3.8. Metaregression

Metaregression was performed to explore the factors influencing the association of MUC expression with OS and DFS/RFS in CRC. None of the covariates (cut-off value, antibody, TNM stage, country, and years) analyzed were identified as potential sources of heterogeneity (Table3).Table 3
Results of meta-regression analysis exploring the source of heterogeneity with OS and DFS/RFS.
Mucins phenotype
Covariates
Univariate analysis (OS)
Univariate analysis (DFS)
Coefficient
SE
P value
Coefficient
SE
P value
MUC1
Antibody
0.055
0.087
0.538
-0.142
0.882
0.883
Cut-off value
0.0297
0.032
0.369
0.155
0.295
0.635
TNM stage
0.365
0.324
0.281
0.773
1.106
0.535
Country
0.048
0.462
0.323
0.155
0.295
0.635
Year
-0.001
0.014
0.964
-0.077
0.115
0.552
MUC2
Antibody
-0.204
0.215
0.367
0.550
0.252
0.094
Cut-off value
-0.027
0.043
0.552
-0.030
0.221
0.898
TNM stage
-0.309
0.124
0.054
-0.270
0.838
0.763
Country
0.007
0.048
0.891
0.180
0.050
0.023
Year
0.036
0.030
0.264
0.108
0.030
0.022
MUC5AC
Antibody
0.464
0.269
0.135
-0.139
0.434
0.769
Cut-off value
0.187
0.158
0.282
-0.248
0.193
0.288
TNM stage
0.923
0.211
0.055
-0.652
0.961
0.546
Country
0.250
0.240
0.339
-0.379
0.293
0.287
Year
0.135
0.073
0.859
0.102
0.069
0.236


## 4. Discussion

In this meta-analysis, we assessed the association between MUC expression levels in CRC tissues and prognosis and investigate the associations between MUC expression levels and several CRC clinicopathological characteristics. Interestingly, findings demonstrated no association between combined MUC phenotype expression levels in CRC tissues and prognosis. However, in subgroup analyses stratified by MUC phenotype, a high level of MUC1 expression was associated with poor OS and DFS/RFS, a high level of MUC2 expression was associated with improved OS and DFS/RFS, and a high level of MUC5AC was associated with improved DFS/RFS. Generally, heterogeneity between studies was significantly reduced in the subgroup analyses stratified by MUC phenotype. Meanwhile, meta-regression analysis revealed that antibody for MUC, cut-off value for MUC, TNM stage, and histologic type were not significant sources of heterogeneity.However, importantly, several studies have shown a correlation between MUC expression and patient with various cancers. For example, a meta-analysis reported that MUC expression was significantly higher in patients with esophageal adenocarcinoma than in normal squamous esophageal mucosa [71]. The study by Lu et al. [72] also indicated that increased MUC expression was associated with worse OS and more detrimental clinicopathological outcomes in head and neck cancer patients. Overall, it is reasonable that the expression of MUC was associated with variable clinical outcomes in different tumors. These differences may be due to different mechanisms, pathways, and treatment options. An earlier meta-analysis have shown that abnormal expression of MUC in CRC tissues compared with healthy mucosa plays an important role in the pathogenesis and progression of CRC [73]. Several meta-analyses have explored the association between MUC expression and CRC clinicopathological characteristics [74–76]. Furthermore, compared with two earlier meta-analyses for various types of cancer by Xu et al. [77] and Huang et al. [78], the present analysis not only added additional 26 and 27 studies in colorectal cancer subtype but also examined the correlation between MUC expression and the clinicopathological factors of colorectal cancer.The current study explored the association between MUC expression levels in CRC tissues and CRC clinicopathological characteristics. A high level of MUC1 expression was associated with CRC in the rectum, deeper invasion, lymph node metastasis, distant metastasis, advanced tumor stage, and lymphatic invasion. Elevated MUC2 expression was associated with CRC in the colon, shallower lesions, negative lymph node metastasis, early stage of tumor, mucinous carcinoma, and larger tumor size. MUC5AC was more easily expressed in colon cancer. These findings implicate MUC1 in mechanisms that promote tumor invasion, lymph node metastasis, high stage, lymphatic invasion, and poor survival in CRC, while MUC2 may have a protective role. A number of studies have demonstrated a unique role for MUC in proliferation, survival, metastasis, epithelial-mesenchymal transition, and antiapoptosis in tumors [13, 17, 79–82]. As a ligand of cell adhesion molecules, MUC 1 induces circulating tumor cells (CTCs) to adhere to endothelial cells or transport to distant sites, establishing secondary tumors [81]. MUC2 is major structural component of the inner mucus layer in the colon, which is impervious to bacteria and protects the colon epithelium. Decreased MUC2 expression allows bacteria to contact the epithelial surface, triggering inflammatory bowel disease, which can lead to colon cancer [83]. Studies characterizing the function of MUC5AC are scarce. Hoshi et al. [84] showed that MUC5AC protects pancreatic cancer cells from TRAIL-induced apoptosis, while other reports suggest that MUC5AC has no effect on cell growth, cell survival, proliferation, or morphology in vitro [85].Findings from the current meta-analysis indicate MUC1 may be a biomarker of poor prognosis in CRC and suggest that combined detection of MUC1 and MUC2 should be used to accurately predict CRC progression, metastasis, and treatment outcomes. Understanding the association between MUC expression levels and metastasis in CRC may help clarify the risk of metastasis at the time of diagnosis in patients with CRC, especially in those patients without symptoms or signs of metastasis. Clinically, MUC detection is simple and easy to implement.This study was associated with several limitations. First, HRs from some of the included studies were calculated from Kaplan-Meier curves, which may have influenced the robustness of our findings. Second, the lack of a standardized detection methods and antibodies to detect MUC status may have affected the accuracy of our results. Third, despite the use of subgroup analysis and meta-regression to identify potential sources of heterogeneity between studies, they may have been additional sources of heterogeneity that impacted our findings. Finally, the sample size was small, and results should be considered preliminary.In conclusion, findings from the current study suggest that MUC1 and MUC2 expression levels in CRC tissues are associated with OS, DFS/RFS, tumor site, depth of invasion, lymph node metastasis, distant metastasis, tumor stage, histologic type, and lymphatic invasion. These results indicate that MUC status can be used to differentiate between normal cells and CRC cells and predict a patient’s clinicopathological characteristics and prognosis. The clinical relevance of MUC regulation in CRC tissues remains to be elucidated in large well-designed cohort studies.



---

*Source: 2391670-2019-12-20.xml*